Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.70 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.69 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797534 | 0.87 | MAPT (0.59) | MAPTFFAR1MDM2STING1HTT | |
| SCHEMBL3873527 | 0.86 | MAPT (0.57) | MAPTFFAR1MDM2TP53KDM4E | |
| SCHEMBL2339500 | 0.85 | GAA (0.70) | MAPTFFAR1MDM2TP53HTT | |
| SCHEMBL27797552 | 0.84 | ALDH1A1 (0.56) | MAPTFFAR1MDM2KDM4EALDH1A1 | |
| SCHEMBL3871921 | 0.84 | TSHR (0.56) | MAPTFFAR1MDM2KDM4EALDH1A1 | |
| SCHEMBL2054558 | 0.82 | MDM2 (1.00) | MAPTFFAR1MDM2TP53HTT | |
| SCHEMBL2054561 | 0.82 | MDM2 (1.00) | MAPTFFAR1MDM2TP53HTT | |
| SCHEMBL2054556 | 0.82 | MDM2 (1.00) | MAPTFFAR1MDM2TP53HTT | |
| SCHEMBL2098298 | 0.82 | MDM2 (1.00) | MAPTFFAR1MDM2TP53HTT | |
| SCHEMBL29921540 | 0.82 | MDM2 (1.00) | MAPTFFAR1MDM2TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| CN-101686952-A | Novel agents of calcium ion channel modulators | VM DISCOVERY INC | 2010-03-31 | — | — | CN | claimed |
| US-8586619-B2 | Agents of calcium ion channel modulators | VM THERAPEUTICS LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | disclosed |
| CN-101686952-A | Novel agents of calcium ion channel modulators | VM DISCOVERY INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | MAPT 1266/4885FFAR1 1437/4885MDM2 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.